



Elekta's New Radiation Oncology Technology to Shape the Future of Cancer Care

Worldwide unveiling of radiation delivery technology will be held March 1 in Atlanta, USA

STOCKHOLM and ATLANTA, February 4 – At an exclusive event scheduled March 1, 2013, Elekta will reveal a leap forward in radiation oncology and the care of individuals with cancer worldwide.

Founded in 1972, Elekta was the first to bring a completely digital linear accelerator to the market, as well as the first to fully integrate imaging technology in the treatment system. Elekta is a market-leading developer of cancer care and neuroscience solutions, including a world-class portfolio of linear accelerators, dedicated radiosurgery and brachytherapy systems and oncology information and treatment planning software solutions.

“At Elekta, we are united by a passion that drives us to constantly strive toward the development of new cancer care solutions that benefit patients, caregivers and healthcare systems,” says Elekta's President and CEO Tomas Puusepp. “It is this unrelenting dedication to patients and their healthcare providers that has inspired our efforts to create a truly singular technological solution in radiation oncology.”

The worldwide unveiling event will be held Friday, March 1 at the Renaissance Atlanta Waverly Hotel, Atlanta, Georgia, USA, 11:00-12:00 EST (17:00-18:00 CET). To attend or view live online, register at www.elekta.com/revealed.

Following the unveiling event, Elekta will host an investor telephone conference with President and CEO Tomas Puusepp on March 1, 12:30 EST (18:30 CET).

To take part in the conference call, please dial in about 5-10 minutes in advance and use the access code 927782.

- Swedish dial-in number: +46 (0)8 5052 0110
- UK dial-in number: +44 (0)20 7162 0077
- US dial-in number: +1 877 491 0064

The telephone conference will also be broadcasted over the internet (audio only). Please use the link: http://webevents.services.reg.meeting-stream.com/73936_elekta/

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on February 4, 2013.

Availability of product will be subject to local regulatory clearance.

###

For further information, please contact:

Johan Andersson Melbi, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: johan.anderssonmelbi@elekta.com
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

**About ElektA**

ElektA is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, ElektA aims to improve, prolong and even save patient lives.

Today, ElektA solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. ElektA employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTA. Website: www.elektA.com.